What Happened to COVID-19 Tests?
COVID-19 tests have evolved from an emergency response tool during the pandemic's peak to an integrated component of broader respiratory virus surveillance and personal health management. While demand for single-purpose COVID-19 tests has declined from its peak, the market for at-home and multiplex tests (detecting COVID-19, flu, and RSV) continues to grow, reflecting a shift towards self-care and endemic disease management. Wastewater surveillance remains a crucial public health tool for tracking viral activity at a community level.
Quick Answer
COVID-19 tests have transitioned into an endemic phase, becoming a regular part of respiratory virus diagnostics. As of May 2026, at-home rapid antigen tests remain widely available and effective against circulating variants, often integrated into multiplex kits that also detect influenza and RSV. Public health efforts increasingly rely on wastewater surveillance for community-level tracking, while individual testing is driven by seasonal waves, self-care trends, and the need for rapid results to limit spread. The market for these tests is stabilizing, with a focus on convenience, accuracy, and multi-pathogen detection.
📊Key Facts
📅Complete Timeline14 events
COVID-19 Outbreak Begins
A new type of coronavirus, later named SARS-CoV-2, breaks out in Wuhan, Hubei Province, China, marking the beginning of the global pandemic.
WHO Declares Pandemic
The World Health Organization (WHO) officially declares COVID-19 a global pandemic, leading to an urgent worldwide demand for diagnostic testing.
Rise of At-Home Testing
Over 100 at-home self-testing kits for COVID-19 receive approval from the US FDA, significantly expanding access to rapid diagnostics.
WHO Ends Public Health Emergency
The World Health Organization declares an end to the Public Health Emergency of International Concern (PHEIC) for COVID-19, signaling a shift towards long-term management.
HHS Relaunches Free At-Home Testing
The U.S. Department of Health and Human Services (HHS) confirms the relaunch of the federal government's initiative for free at-home COVID-19 testing.
BA.3.2 Variant First Identified
The highly mutated SARS-CoV-2 BA.3.2 variant is first identified in a respiratory sample in South Africa, later spreading globally.
iHealth Launches 3-in-1 Combo Test
iHealth Inc. launches its 3-in-1 COVID-19/Flu A and B Rapid Test Kit, reflecting a growing trend towards multiplex diagnostics for respiratory infections.
FDA Fully Approves Omicron-Adapted Vaccines
The FDA grants full approval for Omicron-adapted COVID-19 vaccines and approves the 2025-2026 vaccine formulations from Pfizer/BioNTech and Moderna, targeting the LP.8.1 sublineage.
First US Clinical Detection of BA.3.2
The first instance of the BA.3.2 variant in a clinical specimen in the United States is documented, following earlier detections in wastewater and travelers.
COVID Testing Kit Market Decline
The overall COVID Testing Kit Market is valued at USD 7.01 billion in 2026, projected to decline at a CAGR of -6.32% to USD 5.06 billion by 2031, indicating a shift from pandemic-era demand.
FDA Continues OTC Test Listings
The FDA continues to update and list authorized at-home over-the-counter (OTC) COVID-19 diagnostic tests, ensuring ongoing access for self-testing.
Studies Highlight Testing Limitations
Studies published in March 2026 underscore that COVID-19 testing performance is influenced by behavioral, biological, and logistical factors beyond just assay accuracy.
XFG.1.1 Dominant Variant
The XFG.1.1 variant becomes the dominant COVID-19 variant nationwide in the U.S., accounting for 32% of cases, as reported by infectious diseases experts.
At-Home Test Market Shows Growth
The global at-home COVID-19 diagnostic test kit market is valued at USD 8.34 billion in 2026 and is projected to grow to USD 11.24 billion by 2035, driven by evolving healthcare behaviors and multiplex kits.
🔍Deep Dive Analysis
The trajectory of COVID-19 tests has mirrored the pandemic's evolution, moving from an urgent, global scramble for diagnostic capacity to a more integrated and routine aspect of public health and personal healthcare. Initially, the onset of the COVID-19 pandemic in late 2019 and early 2020 spurred an unprecedented demand for diagnostic tests, primarily PCR tests, to identify infections and control spread. Emergency Use Authorizations (EUAs) by regulatory bodies like the FDA facilitated the rapid deployment of numerous testing solutions, including the eventual widespread availability of rapid antigen tests.
The peak demand for COVID-19 testing occurred in 2020 and 2021, leading to a massive expansion of manufacturing and laboratory infrastructure. Companies like Cue Health saw significant investment and growth during this period. However, as vaccination rates climbed and the virus transitioned into an endemic state, the demand for single-purpose COVID-19 tests began to decline, leading to market adjustments and layoffs for some manufacturers by early 2023.
A key turning point was the World Health Organization's declaration of the end of the Public Health Emergency of International Concern in May 2023, signaling a shift in global strategy. This period saw a pivot towards integrating COVID-19 testing into broader respiratory pathogen surveillance. By 2024 and 2025, the market began to emphasize multiplex diagnostic kits capable of simultaneously detecting COVID-19, influenza A and B, and RSV from a single sample. This innovation addressed the challenge of overlapping symptoms during respiratory seasons and catered to a growing self-care culture.
As of May 2026, at-home testing remains a vital component of COVID-19 management. The FDA continues to list authorized over-the-counter (OTC) tests, and the federal government relaunched initiatives for free at-home tests in August 2024. These tests are generally effective against newer variants, as the antigens they target have remained relatively stable despite viral mutations. The global at-home COVID-19 diagnostic test kit market was valued at USD 8.34 billion in 2026 and is projected to grow, indicating sustained demand for convenient self-testing solutions.
Public health surveillance has also evolved, with wastewater monitoring becoming a critical, low-cost early warning system for tracking the incidence of SARS-CoV-2, influenza, and RSV at a community level. This method provides valuable insights into viral activity, especially as clinical testing and reporting have decreased significantly since 2023. While the overall COVID Testing Kit Market is projected to decline from its pandemic peak, the broader respiratory diagnostics market, including multiplex and at-home tests, is experiencing steady growth, driven by ongoing seasonal waves and the need for comprehensive infectious disease management.
What If...?
Explore alternate histories. What if COVID-19 Tests made different choices?